Patents by Inventor Jung-Hee Kwon

Jung-Hee Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same
    Patent number: 10092658
    Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 9, 2018
    Assignee: PHI BIOMED CO., LTD.
    Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon
  • Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma
    Patent number: 10017823
    Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: July 10, 2018
    Assignee: CBS BIOSCIENCE, CO., LTD
    Inventors: Jin-Young Park, Young-Ho Moon, Jung-Hee Kwon
  • METHOD FOR PREDICTING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR
    Publication number: 20180030541
    Abstract: The present invention relates to a method for predicting sensitivity to treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, by using a biomarker. An effective means and anticancer therapy for cancer treatment of liver cancer are selected by predicting the effect of treatment with VEGFR inhibitors on liver cancer patients through the present invention, thereby increasing the treatment effect and minimizing the side effects of liver cancer treatment.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 1, 2018
    Applicants: CBSBIOSCIENCE INC., GIL MEDICAL CENTER
    Inventors: Jin Young Park, Young Ho Moon, Jung-Hee Kwon, Yun Soo Kim, Ju Hyun Kim, Duck Joo Choi
  • METHOD FOR PREDICTING RECEPTIVITY TO TARGETED ANTICANCER DRUG
    Publication number: 20170356048
    Abstract: The present invention relates to a method for predicting sensitivity to treatment with a vascular endothelial growth factor receptor (VEGFR) inhibitor. According to the present invention, effects on the treatment of liver cancer patients with a vascular endothelial growth factor receptor (VEGFR) inhibitor are predicted. Based on the prediction, an effective means and anticancer therapy for treatment of liver cancer are selected, thereby increasing treatment effects and minimizing the side effects of liver cancer treatment.
    Type: Application
    Filed: July 17, 2015
    Publication date: December 14, 2017
    Inventors: Jin Young PARK, Young Ho Moon, Jung-Hee Kwon
  • ANALYTICAL METHOD FOR INCREASING SUSCEPTIBILITY OF MOLECULAR TARGETED THERAPY IN HEPATOCELLULAR CARCINOMA
    Publication number: 20150376715
    Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.
    Type: Application
    Filed: April 16, 2014
    Publication date: December 31, 2015
    Applicant: CBS BIOSCIENCE, CO., LTD
    Inventors: Jin-Young PARK, Young-Ho MOON, Jung-Hee KWON
  • METHOD FOR MANUFACTURING TRANSDERMALLY DELIVERED HYALURONIC ACID-PROTEIN CONJUGATE AND TRANSDERMALLY DELIVERED HYALURONIC ACID-PROTEIN CONJUGATE MANUFACTURED USING SAME
    Publication number: 20150056254
    Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.
    Type: Application
    Filed: February 7, 2013
    Publication date: February 26, 2015
    Applicant: PHI BioMed Co., Ltd.
    Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon